Use of Cangrelor for Patients Undergoing Coronary Artery Bypass Grafting: Insights From the CAMEO Registry
Recommended Citation
Rymer JA, Page C, Alhanti B, Pichan C, Kansal A, Bhatt DL, Kochar A, Angiolillo DJ, Diaz M, Wimmer NJ, Ang L, Bach R, Jenkins R, Brothers L, Jones WS, Washam JB, Wang TY, Narcisse DI, Basir MB, Chaturvedi A, and Waksman R. Use of Cangrelor for Patients Undergoing Coronary Artery Bypass Grafting: Insights From the CAMEO Registry. JACC Adv 2025;4(12 Pt 2):102280.
Document Type
Article
Publication Date
12-1-2025
Publication Title
JACC Adv
Keywords
CABG; cangrelor
Abstract
BACKGROUND: Little is known about the use of cangrelor in patients with acute myocardial infarction (AMI) undergoing coronary artery bypass grafting (CABG).
OBJECTIVES: The purpose of this study was to examine characteristics and patterns of cangrelor utilization of CABG patients in CAMEO (Cangrelor in Acute Myocardial Infarction: Effectiveness and Outcomes), a multicenter registry of AMI patients receiving cangrelor and/or oral P2Y12 inhibitors.
METHODS: We examined characteristics and patterns of cangrelor utilization in AMI patients who underwent CABG. Patients receiving cangrelor post-CABG were excluded. "Bridge" dosing was defined as cangrelor ≤1 μg/kg/min and percutaneous coronary intervention (PCI) dosing (>1 and ≤ 4 μg/kg/min).
RESULTS: In CAMEO, 246 patients underwent CABG (42.3% received cangrelor). Of these, 30.9% received cangrelor only, 11.4% received an oral P2Y12 inhibitor and cangrelor, 8.9% received an oral P2Y12 inhibitor followed by cangrelor, 21.1% received an oral P2Y12 inhibitor only, and 36.6% received neither. The median age was 63 vs 66 years in cangrelor- vs non-cangrelor-treated patients. Patients treated with cangrelor were more likely to have PCI during hospitalization (P < 0.001) and less likely to have radial access (P = 0.005). Time from admission to CABG and overall length of stay was shorter for cangrelor- vs non-cangrelor-treated patients (median 3.8 vs 5.1 days; 10.5 vs 12.7 days). Among cangrelor-treated CABG patients, 26% received the "bridge" dose, 64% received the PCI dose, and 10% received a combination of both.
CONCLUSIONS: Cangrelor use in patients with AMI undergoing CABG varies, with over 25% of cangrelor-treated patients receiving "bridge" dosing prior to CABG. Timing from hospital admission to CABG and overall length of stay were significantly shorter in cangrelor-treated patients.
PubMed ID
41240514
Volume
4
Issue
12 Pt 2
First Page
102280
Last Page
102280
